A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
← catalyst calendarSponsored by Insmed Incorporated (industry) · INSM — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
288actual
Sites
100
Countries
Argentina, Australia, Belgium +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-30 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-30 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Rhinosinusitis Without Nasal Polyps
Interventions
- Drug: Brensocatib — also filed as INS1007
- Drug: Placebo
- Drug: Mometasone furoate nasal spray (MFNS)
Primary outcome
what the primary-completion date above is the date OFChange From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24
measured Baseline and Week 24
Permalink · INSM's whole pipeline · Catalyst calendar · Every registered study · What changed